The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigation of clonal hematopoiesis frequency following PARP inhibitor treatment and its association with prior platinum therapy exposure.
 
Lea Moukarzel
No Relationships to Disclose
 
Jeremy Baeten
No Relationships to Disclose
 
Irenaeus Chan
No Relationships to Disclose
 
Giulia Petrone
No Relationships to Disclose
 
Jie Liu
No Relationships to Disclose
 
Duc Tran
No Relationships to Disclose
 
Kenneth Offit
Patents, Royalties, Other Intellectual Property - Patent pending on therapeutic applications of targeting ERCC3 mutations in cancer. Diagnosis & treatment of ercc3-mutant cancer US20210137850A1
Other Relationship - AnaNeo Therapeutics
 
Ethan Barnett
Stock and Other Ownership Interests - Biondvax; Gilead Sciences
 
Wassim Abida
Honoraria - Aptitude Health; Clinical Education Alliance; Medscape; OncLive/MJH Life Sciences; Pfizer; Prostate Cancer Foundation; Roche; theMedNet; touchIME
Consulting or Advisory Role - AstraZeneca/MedImmune; Boundless Bio; Clovis Oncology; Daiichi Sankyo; Endeavor BioMedicines; Janssen; K36 Therapeutics; Laekna Therapeutics; MOMA Therapeutics; ORIC Pharmaceuticals; Pfizer
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst); Epizyme (Inst); Merus (Inst); MOMA Therapeutics (Inst); Nuvation Bio (Inst); ORIC Pharmaceuticals (Inst); TransThera Biosciences (Inst); Zenith Epigenetics (Inst)
(OPTIONAL) Uncompensated Relationships - Nuvation Bio
 
Alison Schram
Consulting or Advisory Role - Blueprint Medicines; Endeavor BioMedicines; Flagship Pioneering; Mersana; Merus NV; PMV Pharma; Redona Therapeutics; Relay Therapeutics; Repare Therapeutics; Schrodinger
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - PMV Pharma
 
Britta Weigelt
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - Repare Therapeutics (I)
Consulting or Advisory Role - Bain Capital Life Sciences (I); PAIGE (I); Repare Therapeutics (I); SAGA Diagnostics (I); Volition RX (I)
Research Funding - Repare Therapeutics (Inst); SAGA Diagnostics (Inst)
 
Mary Mullen
No Relationships to Disclose
 
Carlos Cruchaga
No Relationships to Disclose
 
Howard Scher
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - AIQ Global; Bayer; Genzyme; Janssen Research & Development; Novartis; Pfizer; Promontory Therapeutics; Regeneron; WIRB-Copernicus Group
Research Funding - AIQ Solutions (Inst); Astrin Biosciences (Inst); Biodesix (Inst); Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Elucida Oncology - Intellectual Property Rights
Travel, Accommodations, Expenses - Bayer; Biodesix; Epic Sciences; Promontory Therapeutics; Prostate Cancer Foundation; WIRB-Copernicus Group
 
Ross Levine
Leadership - Qiagen
Stock and Other Ownership Interests - Ajax; Anovia; Auron Therapeutics; BAKX Therapeutics; C4 Therapeutics; Epiphanes; Imago Pharma; IsoPlexis; Kurome Therapeutics; Loxo; Mana Therapeutics; Mission Bio; Prelude Therapeutics; Qiagen; Scorpion Therapeutics; Syndax; Zentalis
Honoraria - Amgen; Celgene; Genome Canada; Gilead Sciences; Incyte; Janssen; Lilly; The Mark Foundation For Cancer Research
Consulting or Advisory Role - BMS; Bridge Medicines; Bridge Therapeutics; Bridgebio; C4 Therapeutics; Celgene; Daiichi; Imago Pharma; IsoPlexis; Jubilant Biosys; Loxo; MorphoSys; Novartis; Prelude Therapeutics; Roche; Stelexis Therapeutics; Vida Ventures
Speakers' Bureau - Amgen; Lilly
Research Funding - Celgene; Cure Breast Cancer Foundation; ECOG-ACRIN; Prelude Therapeutics; Roche; The Mark Foundation For Cancer Research
Travel, Accommodations, Expenses - Auron Therapeutics; C4 Therapeutics; Constellation Pharmaceuticals; Genome Canada; Incyte; Qiagen
 
Elli Papaemmanuil
Leadership - Isabl Technologies
Stock and Other Ownership Interests - Isabl Technologies; TenSixteen Bio
Honoraria - Celgene; Novartis
Consulting or Advisory Role - TenSixteen Bio
Speakers' Bureau - Illumina
Research Funding - Celgene
Travel, Accommodations, Expenses - Celgene; Illumina; Novartis
 
Karen Cadoo
Honoraria - Pfizer; Roche Ireland
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; MSD; NextCure
Research Funding - Immunogen (Inst); MSD (Inst); The Irish Cancer Society (Inst)
Travel, Accommodations, Expenses - Roche
 
Daniel Link
No Relationships to Disclose
 
Kelly Bolton
Consulting or Advisory Role - SERVIER
Research Funding - Bristol Myers Squibb Foundation; SERVIER